Inflammation-Driven Prognosis in Advanced Heart Failure: A Machine Learning-Based Risk Prediction Model for One-Year Mortality

炎症驱动的晚期心力衰竭预后:基于机器学习的一年死亡率风险预测模型

阅读:1

Abstract

BACKGROUND: To develop a machine learning (ML)-based prediction model focused on the one-year mortality risk in patients with advanced heart failure (AdHF), aiming to improve prediction accuracy by integrating inflammatory biomarkers and clinical parameters, assist clinical decision-making, and enhance patient outcomes. METHODS: A retrospective cohort study. Data were obtained from the electronic medical records system of the Affiliated Hospital of Xuzhou Medical University. AdHF patients admitted to the ICU and cardiology department from January 2015 to December 2023 were included with a one-year follow-up. 52 variables potentially affecting prognosis were incorporated. The LASSO algorithm was used for feature selection and dimensionality reduction. Data were split into training and validation sets. Seven ML algorithms were applied to build and evaluate models. The SHAP method was used for model analysis and a dynamic nomogram was created. RESULTS: The study included 715 AdHF patients. The random forest (RF) model performed best, with an area under the curve (AUC) of 0.83 (95% confidence interval: 0.77-0.88), an accuracy of 0.72, a sensitivity of 0.74, and an F1 score of 0.73. Key predictors of one-year mortality risk included Beta blockers, ACEI/ARB/ARNI, BNP, CRP, NLR, AF, MI, NYHA class, and age. SHAP analysis revealed that elevated CRP, NLR, and age were associated with increased risk, while Beta blockers, ACEI/ARB/ARNI, and lower BNP values were associated with reduced risk. An online dynamic nomogram was developed to provide personalized risk predictions based on patient-specific conditions. CONCLUSION: A successful ML-based prediction model was developed to accurately predict the one-year mortality risk in AdHF patients, with inflammation-driven factors being significant. The RF model integrating clinical features and inflammatory markers showed excellent performance and could assist clinical decision-making. Future research should conduct larger, multi-center, and prospective studies to further validate these findings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。